We have located links that may give you full text access.
The Optimum Operative Time of Revascularization for Patients with Moyamoya Disease Following Acute Onset.
World Neurosurgery 2018 June
OBJECTIVE: Whether surgery should be performed in patients with acute onset of moyamoya disease (MMD) is controversial. This study aimed to determine optimum operative time for patients with MMD.
METHODS: We retrospectively analyzed 57 patients with MMD admitted between January 2016 and June 2017. All patients consented to combined revascularization. Considering the time interval between acute onset of MMD and surgery, we divided all patients into an early group and later group (>90 days between MMD onset and surgery). We compared postoperative complications, neurologic improvement, and favorable outcome between groups to estimate optimum operative time of revascularization.
RESULTS: More patients in the early group presented with ischemic events compared with the later group (18/28 vs. 11/29, P = 0.047). The difference in worst preoperative mRS score (≥3) between groups was not statistically significant (3/28 vs. 3/29, P = 0.964). Rate of postoperative complications in the early group was significantly higher than in the later group (39.2% vs. 13.7%, P = 0.029). There was neurologic improvement in 50.0% of patients in the early group and 75.9% of patients in the later group (P = 0.043). The rate of favorable outcome after revascularization in the later group (89.7%) was higher than in the early group (78.6%), but there was no significant difference (P = 0.251).
CONCLUSIONS: It seems more reasonable to opt for delayed revascularization for patients with acute-onset MMD, but the decision must take into account the morbidity of ongoing ischemic or hemorrhagic events.
METHODS: We retrospectively analyzed 57 patients with MMD admitted between January 2016 and June 2017. All patients consented to combined revascularization. Considering the time interval between acute onset of MMD and surgery, we divided all patients into an early group and later group (>90 days between MMD onset and surgery). We compared postoperative complications, neurologic improvement, and favorable outcome between groups to estimate optimum operative time of revascularization.
RESULTS: More patients in the early group presented with ischemic events compared with the later group (18/28 vs. 11/29, P = 0.047). The difference in worst preoperative mRS score (≥3) between groups was not statistically significant (3/28 vs. 3/29, P = 0.964). Rate of postoperative complications in the early group was significantly higher than in the later group (39.2% vs. 13.7%, P = 0.029). There was neurologic improvement in 50.0% of patients in the early group and 75.9% of patients in the later group (P = 0.043). The rate of favorable outcome after revascularization in the later group (89.7%) was higher than in the early group (78.6%), but there was no significant difference (P = 0.251).
CONCLUSIONS: It seems more reasonable to opt for delayed revascularization for patients with acute-onset MMD, but the decision must take into account the morbidity of ongoing ischemic or hemorrhagic events.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Systemic lupus erythematosus.Lancet 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app